In stroke medicine, critical decisions often unfold within minutes. A patient is able to speak, can move their limbs with minimal impairment, and presents with a low NIHSS score. Such a clinical picture is frequently labeled as mild, yet if an angiogram reveals a large-vessel occlusion, the risk of rapid neurological deterioration persists over the following hours.

The clearest data addressing this gray area emerged from the MILD-MT trial, published in the New England Journal of Medicine in late 2026.1 The study compared mechanical thrombectomy plus medical management against medical therapy alone in patients with a mild clinical presentation but a large-vessel occlusion in the anterior circulation. The primary endpoint was a modified Rankin score of 0 to 1 at 90 days, indicating that the patient returned largely independently to their daily life.

Key Takeaways from the Trial
  • In the MILD-MT trial, the rate of a 90-day modified Rankin score of 0-1 reached 69.4 percent in the thrombectomy arm compared to 50 percent in the medical arm.
  • Symptomatic cerebral hemorrhage occurred in three patients in each group, while serious procedural complications in the intervention arm were reported at 13.2 percent.
  • The clinical message is nuanced: benefits exist for correctly selected mild stroke patients, but this does not imply that every mild stroke patient requires the procedure.
  • Imaging-based patient selection and institutional experience remain decisive factors in the decision-making process.

Why do mild stroke symptoms carry high risks of rapid deterioration?

The MILD-MT trial was conducted in China as a multicenter, randomized, open-label study. It enrolled patients with an NIHSS score under 6, a large-vessel occlusion in the anterior circulation, a small infarct core, and a large perfusion mismatch. The time window extended up to 24 hours from symptom onset. This selection targeted a patient group bearing early deterioration risks despite appearing mild upon initial external observation.

A total of 304 patients underwent randomization, with 300 entering the modified intention-to-treat analysis. The thrombectomy plus medical treatment arm comprised 144 patients, while the medical-therapy-only arm included 156 patients.1

Notes and Sources

  1. Liu J, Yi T, Xing P et al. Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion. New England Journal of Medicine, 2026. DOI: 10.1056/NEJMoa2609149. 304 randomizations, 300 mITT analysis; primary endpoint mRS 0-1, 90 days. ↩
  2. Secondary outcomes verified via JournalFilter summary and NEJM abstract text: mRS 0-2, Barthel, and safety signals. Source: journalfilter.com/neurology/article/42929671. ↩

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. In suspected stroke cases, calling emergency services and obtaining prompt physician evaluation is essential.